You are reading one round. Fundz also knows which of your own LinkedIn connections can open this account.See it live →
Medicus Pharma Ltd. Terminates Standby Equity Purchase Agreement
PUBLIC · MDCXSep 11, 2026•4 days ago
Amount Raised
$15 Million
Round Type
Funding Round
TorontoBiotechnologyHealthcareTherapeutics
Investors
Ya Ii Pn, Ltd.
Description
On September 11, 2026, Medicus Pharma Ltd. and YA II PN, LTD. mutually agreed to terminate the Standby Equity Purchase Agreement. This agreement allowed Medicus to issue and sell up to $15.0 million in common shares
Company Information
Company
Medicus Pharma
Location
100 KING STREET WEST
Toronto, Ontario, Canada
About
Medicus Pharma Ltd. (NASDAQ:MDCX) is a biotech/life sciences company focused on accelerating the clinical development programs of novel and potentially disruptive therapeutic assets.
The Company is currently advancing the clinical development program of its novel Doxorubicin containing Microneedle Array (D-MNA) treatment to non-invasively treat basal cell carcinoma of the skin (BCC).
Medicus is also developing Teverelix, a next generation GnRH Antagonist as a first in class market product for Acute Urinary Retention (AURr) and high CV risk Prostate Cancer.
D-MNA and Teverelix, collectively represent ~$8 billion in potential market opportunity.
Don't miss Medicus Pharma's next move
Get an email the moment Medicus Pharma raises, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Related People
Suggested for you
1 contact
Predictive Intelligence
Strategic
ML-powered predictions for Medicus Pharma's next move
TorontoBiotechnologyHealthcareTherapeutics